CSI Market
Sign In | Register

Supernus Pharmaceuticals inc (SUPN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SUPN quarterly Cash Flow →
The table below presents a historical view of Supernus Pharmaceuticals inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-38.55
Depreciation & amortization91.56
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability25.42
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-5.58
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation33.05
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increase Decrease In Deferred Product Revenue Net-
Noncash Interest Expense Income-
Increase Decrease In Accrued Sales Deductions-
Interest Expense Non Recourse Royalty Liability-
Revenue From Royalty Agreement-
Amortization Of Operating Lease Assets-
Noncash Operating Lease Cost-
Increase Decrease In Accrued Product Returns And Rebates-7.61
Marketable Securities Realized Gain Loss-
Payments For Proceeds From Collaborative Arrangement Investment-
Debt Securities Available For Sale Realized Gain-
Impairment Of Intangible Assets Excluding Goodwill-
Investment Income Net Amortization Of Discount And Premium-4.90
Debt Securities Available For Sale Realized Gain Loss7.98
Income taxes5.21
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Accounts Receivable-22.30
Increase (Decrease) in Accounts Payable and Accrued Liabilities-24.57
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-13.18
Other Working Capital0.00
Other Noncash Income (Expense)1.89
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.09
Discontinued operations0.00
Net Cash flow from Operating Activities47.33
Investing Activities
Capital Expenditures-1.34
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities774.48
Payments to Acquire Available-for-sale Securities, Debt-475.94
Real Estate Investments0.00
Increase Decrease In Deferred Legal Fees-
Payments For Deferred Legal Fees-
Payments To Acquire Property Plant And Equipment And Deferred Legal Fees-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-293.09
Payments to Acquire Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Increase (Decrease) in Deferred Charges, Investing0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities4.11
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock37.62
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-99.27
Proceeds From Sale Of Future Royalties-
Purchases Of Convertible Note Hedge-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents69.33
Finance Lease Principal Payments-
Proceeds From Governmental Loans And Grants-
Proceeds From Governmental Loan And Grant-
Restricted Cash Noncurrent1.45
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.13
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow45.99
Total Cash Flow60.57
4 historic quarters locked

Sign in to unlock the full Supernus Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Supernus Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001356576-26-000011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License